Assess, de-risk and optimize for clinical success

Access our comprehensive proprietary line of in silico and in vitro services for manufacturability, immunogenicity, potency assessment, humanization and protein engineering. These technologies include our award winning and proprietary Epibase® T cell epitope screening platform for immunogenicity assessment along with our proprietary technology platform for structural protein engineering which can be followed by potency assessment.

In addition to our protein design and optimization services, we also offer a protein expression service for mg to kg quantities of both non-GMP and GMP material. Our Light Path™ programs are streamlined with minimal scope development and manufacturing services available for both mammalian and microbial applications. Our protein design and optimization services were developed to mitigate risks, reduce attrition and help improve the quality and safety of therapeutic proteins. They also address the challenges and accelerate the design and development of efficacious vaccines.

Learn more about early de-risking


Our locations

Locations where this service is provided


Cambridge, United Kingdom

Early Development Services offer a portfolio of preclinical risk assessment solutions that utilize in silico and in vitro assessment for stability, antibody humanization, protein engineering as well as providing non-GMP protein production services.

Learn more

Early De-risking and Optimization Offerings Catalog

Offerings

Technologies